Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Cut to $9.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective cut by stock analysts at Cantor Fitzgerald from $16.00 to $9.00 in a research note issued on Wednesday, The Fly reports. The firm currently has a “neutral” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 4.53% from the stock’s previous close.

Other analysts have also issued reports about the stock. Citigroup cut their target price on shares of Teva Pharmaceutical Industries from $27.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, April 11th. UBS Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, March 7th. They set a “buy” rating and a $22.00 target price for the company. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 target price for the company. in a research note on Wednesday, March 6th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, SunTrust Banks started coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, March 19th. They set a “hold” rating and a $17.00 target price for the company. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $17.05.

TEVA stock traded down $0.10 on Wednesday, hitting $8.61. 15,636,077 shares of the company’s stock traded hands, compared to its average volume of 13,228,337. Teva Pharmaceutical Industries has a 1-year low of $8.25 and a 1-year high of $25.96. The firm has a market cap of $8.86 billion, a PE ratio of 3.08, a P/E/G ratio of 1.09 and a beta of 1.64. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62.



Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. During the same period in the prior year, the business earned $0.94 earnings per share. The business’s quarterly revenue was down 15.2% on a year-over-year basis. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Sol J. Barer acquired 111,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. Insiders have sold 18,860 shares of company stock worth $226,854 in the last 90 days. 0.49% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Kore Private Wealth LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $29,000. Bruderman Asset Management LLC increased its stake in Teva Pharmaceutical Industries by 2,175.0% in the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after buying an additional 2,262 shares during the period. Coastal Investment Advisors Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $37,000. Lindbrook Capital LLC increased its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after buying an additional 945 shares during the period. Finally, Cullen Frost Bankers Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $40,000. Hedge funds and other institutional investors own 65.10% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is an SEC Filing?

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.